In the landmark STEP 1 trial (Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding and colleagues, New England Journal of Medicine , 2021), 1,961 adults who took weekly semaglutide (2.4 mg) plus lifestyle support lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, and 86% achieved at least 5% weight loss
liraglutide is injected daily The longer duration of action is the main reason Wegovy produces greater weight loss Weight loss: what the evidence shows Head-to-head trial: STEP 8 Unlike many medication comparisons, we have a direct head-to-head randomised controlled trial comparing semaglutide and liraglutide for weight loss
The three recommended injection sites are the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm
Talk to your prescriber if you are concerned that your prescription for Rybelsus exceeds the supply covered by your Blue Cross and Blue Shield Association plan (or plan provided by an independent licensee of Blue Cross)
Safety and efficacy of once-weekly semaglutide monotherapy versus placebo in Japanese subjects with type 2 diabetes (SUSTAIN Japan): A 30-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter phase IIIa trial
